Infections reported during treatment with BsAb therapy ([A] data from within clinical trials; [B] real-world data with more than 100 patients included)
| 7A . | Teclistamab . | Elranatamab . | Alnuctamab . | ABBV-838 . | Talquetamab 0.4-0.8 mg/kg . | Cevostamab . | Forimtamig . |
|---|---|---|---|---|---|---|---|
| n = 165 . | n = 123 . | n = 78 . | n = 118 . | n = 288 . | n = 61 . | n = 57 . | |
| Median FU | 14.1 | 10.4 | 11.7 | 4.3-8.0 | 14.9-8.6 | 8.8 | 8.0 |
| Overall | 76.4 | 66.7 | 59 | 32 | 57.3-50.3 | 45 | 45.6 |
| Grade 3-4 | 44.8 | 35 | 17 | 17 | 16.8-11.7 | NR | 26.4 |
| Bacterial | NR | NR | NR | NR | NR | NR | NR |
| Viral | NR | NR | NR | NR | NR | NR | NR |
| COVID-19 (grade 3-4) | 12.1 | 11.4 | 3 | NR | 0.7-2.1 | NR | 3.6 |
| Fungal | NR | NR | NR | NR | NR | NR | NR |
| Opportunistic | |||||||
| PJP | 3.6 | 4.9 | NR | NR | 3.5-2.8 | NR | NR |
| CMV | NR | 8.1 | 2 patients | 0 | 3 patients | NR | NR |
| HGG | 74.5 | 75.5 | 19 | 14 | 64.3-67.7 | NR | NR |
| IGRT | 52.8 | 43.1 | NR | 23 | 14.7-13.1 | NR | NR |
| 7A . | Teclistamab . | Elranatamab . | Alnuctamab . | ABBV-838 . | Talquetamab 0.4-0.8 mg/kg . | Cevostamab . | Forimtamig . |
|---|---|---|---|---|---|---|---|
| n = 165 . | n = 123 . | n = 78 . | n = 118 . | n = 288 . | n = 61 . | n = 57 . | |
| Median FU | 14.1 | 10.4 | 11.7 | 4.3-8.0 | 14.9-8.6 | 8.8 | 8.0 |
| Overall | 76.4 | 66.7 | 59 | 32 | 57.3-50.3 | 45 | 45.6 |
| Grade 3-4 | 44.8 | 35 | 17 | 17 | 16.8-11.7 | NR | 26.4 |
| Bacterial | NR | NR | NR | NR | NR | NR | NR |
| Viral | NR | NR | NR | NR | NR | NR | NR |
| COVID-19 (grade 3-4) | 12.1 | 11.4 | 3 | NR | 0.7-2.1 | NR | 3.6 |
| Fungal | NR | NR | NR | NR | NR | NR | NR |
| Opportunistic | |||||||
| PJP | 3.6 | 4.9 | NR | NR | 3.5-2.8 | NR | NR |
| CMV | NR | 8.1 | 2 patients | 0 | 3 patients | NR | NR |
| HGG | 74.5 | 75.5 | 19 | 14 | 64.3-67.7 | NR | NR |
| IGRT | 52.8 | 43.1 | NR | 23 | 14.7-13.1 | NR | NR |